Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$74.55 USD

74.55
4,962,279

+0.10 (0.13%)

Updated May 16, 2024 03:59 PM ET

After-Market: $74.56 +0.01 (0.01%) 7:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

HealthEquity (HQY) Closes Conduent's BenefitWallet Acquisition

by Zacks Equity Research

HealthEquity (HQY) completes the acquisition of Conduent's BenefitWallet HSA portfolio. This is likely to further strengthen the HSA business of HealthEquity.

Centene (CNC) to Continue Serving Kansas' Medicaid Members

by Zacks Equity Research

Centene's (CNC) subsidiary wins contract from the Kansas Department of Administration to continue providing comprehensive healthcare services to the KanCare program's members.

Reasons to Add Veeva Systems (VEEV) Stock to Your Portfolio

by Zacks Equity Research

Veeva System's (VEEV) strong product demand and strategic deals raise optimism about the stock.

GE HealthCare (GEHC), Medis Medical Partner to Aid CAD Therapy

by Zacks Equity Research

GE HealthCare (GEHC) and Medis Medical collaborate to boost precision care for coronary artery disease treatment.

Urmimala Biswas headshot

3 Solid Buys From MedTech Following 2024 Guidance Raise

by Urmimala Biswas

Guidance hikes by BSX, ALGN and ALC for 2024 make them attractive investment bets.

Are Medical Stocks Lagging Adlai Nortye Ltd. Sponsored ADR (ANL) This Year?

by Zacks Equity Research

Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Boston Scientific (BSX) Gains From MedSurg Growth & Buyouts

by Zacks Equity Research

Within Neuromodulation, Boston Scientific's pain business is consistently gaining traction, banking on strength in the spinal cord stimulation (SCS) business.

Philips' (PHG) Gets FDA Recall for Trilogy Ventilator Glitch

by Zacks Equity Research

Philips' (PHG) software update for Trilogy Evo ventilators is set to mitigate a possible power malfunction and gets FDA Class I recall identification, as it may cause serious harm.

Here's How Much a $1000 Investment in Boston Scientific Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

The Zacks Analyst Blog Highlights Boston Scientific, Arista Networks, Palo Alto Networks, American Electric Power and Cboe Global Markets

by Zacks Equity Research

Boston Scientific, Arista Networks, Palo Alto Networks, American Electric Power and Cboe Global Markets are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Boston Scientific, Arista Networks & Palo Alto Networks

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Boston Scientific Corporation (BSX), Arista Networks, Inc. (ANET) and Palo Alto Networks, Inc. (PANW).

Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Orthofix Medical's (OFIX) Telescopic Nail Gets FDA Clearance

by Zacks Equity Research

Orthofix Medical (OFIX) announces the FDA clearance of its Rodeo Telescopic Nail, which is likely to aid in curing fractures or abnormalities in individuals with osteogenesis imperfecta.

Neogen (NEOG) Faces Macroeconomic Issues, Fierce Competition

by Zacks Equity Research

Neogen (NEOG) faces intense competition from companies ranging from small businesses to divisions of large multinational companies.

AMN Healthcare (AMN) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AMN Healthcare's (AMN) dismal results in the majority of its segments led to a soft overall first-quarter performance.

PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up

by Zacks Equity Research

PacBio (PACB) reports growth in Product revenues in the first quarter of 2024. However, Instruments revenues decline year over year due to lower shipment of Revio units.

Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up

by Zacks Equity Research

Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.

Inogen (INGN) Q1 Earnings Top Estimates, Revenues Up Y/Y

by Zacks Equity Research

Higher business-to-business sales aid Inogen's (INGN) overall first-quarter results.

QuidelOrtho (QDEL) Q1 Earnings Beat Estimates, Margins Fall

by Zacks Equity Research

QuidelOrtho's (QDEL) first-quarter results reflect growth in revenues, excluding the COVID-19 revenue impact.

OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y

by Zacks Equity Research

OPKO Health's (OPK) first-quarter results reflect soft performances despite robust RAYALDEE sales and strength in the Pharmaceuticals segment.

McKesson (MCK) Q4 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

McKesson's (MCK) fourth-quarter fiscal 2024 results showcase growth in the U.S. Pharmaceutical while lower COVID-related sales hurt the Medical Surgical Solutions segment.

Nevro's (NVRO) Q1 Earnings and Sales Beat Estimates, Margins Up

by Zacks Equity Research

Nevro's (NVRO) first-quarter earnings and revenues surpass their respective Zacks Consensus Estimate. The company incurs a loss in the operating level.

Inspire Medical (INSP) Q1 Earnings Beat, Gross Margin Up

by Zacks Equity Research

Inspire Medical's (INSP) both geographic segments witness strong revenue growth in the first quarter.

Masimo (MASI) Q1 Earnings Beat Estimates, '24 EPS View Up

by Zacks Equity Research

Masimo's (MASI) Q1 healthcare revenues reflect strong sensor orders, which were completely offset by lower capital equipment purchases. Sensor production in Malaysia is likely to improve Healthcare gross margin.